Study design
SOLID TUMOUR
This was a Phase 1/2, open-label, multicentre, non-randomised study to investigate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumour activity of BGB-A333 alone and in combination with tislelizumab in patients with advanced solid tumours.The study consisted of two phases, each comprising two parts (Fig. 